In a milestone achievement for global medicine and cancer research, Napoleone Ferrara, MD, has officially been named the recipient of the prestigious 2026 Yergin Family International Prize for Biomedical Research. The landmark honor celebrates Dr. Ferrara’s transformative career, spanning decades of pioneering work in molecular biology that fundamentally altered modern oncology and ophthalmology.
Quick Facts: Dr. Napoleone Ferrara
- Full Name: Napoleone Ferrara, MD
- Field: Molecular Biology, Oncology, Ophthalmology
- Major Breakthrough: Discovery and cloning of Vascular Endothelial Growth Factor (VEGF)
- Blockbuster Therapies Developed: Bevacizumab (Avastin) and Ranibizumab (Lucentis)
- Latest Honor: 2026 Yergin Family International Prize for Biomedical Research
Groundbreaking Breakthroughs: How Napoleone Ferrara Changed Medicine
The journey that led Napoleone Ferrara to this global honor began during his pioneering research tenure at Genentech in the late 1980s. Dr. Ferrara identified, isolated, and successfully cloned vascular endothelial growth factor (VEGF)—a critical signaling protein responsible for angiogenesis, the growth of new blood vessels from existing vascular networks.
Recognizing that tumors rely heavily on angiogenesis to supply oxygen and nutrients required for rapid proliferation, Dr. Ferrara engineered the first generation of anti-VEGF monoclonal antibodies. His visionary work led directly to the development of bevacizumab (widely known as Avastin), an indispensable drug in the clinical management of colorectal cancer, non-small cell lung carcinoma, glioblastoma, and renal cell cancer.
Conquering Blindness: The Creation of Lucentis
Beyond oncology, Dr. Ferrara’s insights revolutionized the management of blinding retinal diseases. Age-related macular degeneration (AMD) was long considered irreversible and untreatable, leaving millions of aging adults worldwide facing catastrophic vision loss.
By translating his angiogenesis models into ocular therapies, Ferrara pioneered ranibizumab (Lucentis). Clinical trials demonstrated unprecedented outcomes: instead of merely slowing deterioration, the drug frequently restored measurable sight in patients suffering from neovascular wet AMD and diabetic retinopathy. Today, anti-VEGF intraocular injections remain the gold-standard global treatment, preserving visual independence for tens of millions across every continent.
Inside the Yergin Family International Prize for Biomedical Research
The Yergin Family International Prize for Biomedical Research stands among the world’s most distinguished honors awarded to visionary scientists whose bench discoveries translate directly into transformative clinical care. Selection committee officials underscored Dr. Ferrara’s dual impact on both oncology and ocular medicine as an extraordinary testament to translational science.
Colleagues and global biomedical leaders praised Ferrara for maintaining rigorous scientific curiosity alongside deep clinical empathy. His sustained research portfolio has generated dozens of worldwide patents, earned top citations across scientific journals, and laid the foundation for next-generation vascular medicines now undergoing clinical evaluation.
Academic Legacy and Ongoing Research
Serving as Distinguished Professor of Pathology and Adjunct Professor of Ophthalmology at the University of California San Diego (UCSD) Moores Cancer Center, Dr. Ferrara continues to mentor rising researchers and steer advanced studies into secondary mechanisms of tumor resistance to anti-angiogenic therapy.
As the biomedical community celebrates the 2026 Yergin Family Prize, Dr. Ferrara’s enduring body of work stands as a reminder that fundamental laboratory discoveries have the power to save lives, prevent blindness, and elevate clinical standards across global healthcare systems.